Our results suggest that oral beta-lactams are a safe and effective step down for patients with E. coli bacteremic urinary tract infections. At baseline, the two treatment groups had similar co-morbidities, severity of infection and duration of intravenous treatment. In this population of bacteremic patients, there was no difference in rates of clinical cure or length of hospitalization. Approximately 30% of patients in our study were male with no significant difference in clinical cure rate compared to females. Mortality and C. difficile infection were infrequent occurrences, with no difference between the groups.
This study isolated a group of bacteremic patients with pyelonephritis to demonstrate the suitability of oral beta-lactam step down and adds to a growing body of literature with similar conclusions. A randomized controlled trial by Sanchez et al compared daily intravenous ceftriaxone to single dose intravenous ceftriaxone followed by oral cefixime, both to total 10 days of treatment [16]. Their study included 144 women with uncomplicated pyelonephritis. E. coli was the responsible organism in nearly all cases and 25% of patients had bacteremia. There was no difference in clinical cure between groups (91% vs 92% respectively). Another randomized controlled trial by Monmaturapoj et al evaluated daily intravenous ceftriaxone to 3 days of intravenous ceftriaxone followed by oral cefditoren, both to total 10 days of treatment [17]. Their study included 82 patients with pyelonephritis, only three of whom were male. E. coli was identified in 84% of cases and 21% of patients had bacteremia. Again, no difference in clinical cure rate was found (95% vs 100% respectively). Both of these randomized controlled trials were limited by the small number of male patients and minority of cases with bacteremia.
A recent observational study by Tamma et al showed similar 30-day mortality in a cohort of hospitalized patients with Enterobacteriacea bacteremia who received oral step down therapy compared to ongoing intravenous therapy [19]. Nearly half the patients in their study were male. A wide range of infections were included, with urinary tract infection comprising 36.5%. However, fluoroquinolones were the most commonly used oral step down therapy (70%), while oral beta-lactams were only used in a minority (16.5%). This reflects the widespread practice of avoiding oral beta-lactams in step down therapy for gram negative bacteremia.
Mercuro et al compared fluoroquinolones to beta-lactams in oral step down for Enterobacteriacea bacteremia [20]. Over 50% of patients were male. E. coli was the dominant organism (71%), with approximately 70% having a urinary tract infection source. No difference in clinical success was noted between the two groups. However, their study included only admitted patients. Over 20% of patients in our study were managed as outpatients, without hospital admission. Furthermore, including a broad range of infections may mask differences between individual subgroups (e.g., urinary tract infections). As a homogenous patient population of bacteremic urinary tract infections our study is not affected by this limitation.
A recent meta-analysis by Punjabi et al found no difference in all-cause mortality between oral beta-lactam and oral fluoroquinolones in step down of Enterbacteriaceae bacteremia [21]. Oral beta-lactams appeared to have higher rates of infection recurrence compared to fluoroquinolones. The authors hypothesize that under-dosing of beta-lactams may be contributing to this finding. Including a wide range of source infections confounds this interpretation.
The impetus to limit fluoroquinolone prescribing is growing. Fluoroquinolone prescribing is an established risk for C. difficile infection, both at the individual and community level [22, 23]. Multiple statements have been issued by Health Canada, the United States Food and Drug Administration, and the European Medicines Association warning about serious and underappreciated side effects [4–10]. For fluoroquinolone prescribing to be curbed, other therapeutic options with similar efficacy and improved safety profile need to be identified. Furthermore, despite the side effects of fluoroquinolones, they fulfil a critical role as oral therapy for difficult to treat gram-negative infections due to Pseudomonas or Acinetobacter. Limiting fluoroquinolone use to these infections where other suitable oral alternatives do not exist is prudent antimicrobial stewardship.
Fluoroquinolones have long been regarded as an effective agent for bacteremic infections. Pharmacologic factors including high oral bioavailability, convenient dosing, and ability to attain dosing targets have supported this practice. This is supported by a large body of controlled literature and extensive real life clinical experience. Oral beta-lactams do not share the same historical confidence in serious invasive infections including bacteremia. Pharmacokinetic concerns including lower oral bioavailability and more frequent dosing are reason for pause. However, recent randomized controlled trials using oral beta-lactams in treatment of infective endocarditis and complex orthopedic infections challenge these historical dogmas [24, 25].
Our study has several limitations. First, its retrospective design limits our ability to control for confounders to those that were collected. Second, selection bias could have been an issue, as unaccounted patient factors may have led a physician to choose a certain oral step down option, or not to step down to oral therapy at all. The use of propensity score analysis can partly account for this confounding. Third, some relevant outcomes may have been missed. Data were abstracted from the Health Authority electronic medical record, thus potentially relevant outcomes only captured in outpatient records were not accessible. Fourth, the convenience sample of one year resulted in a limited sample size. This study may be underpowered to identify a difference between treatment arms where one truly does exist. Fifth, our study excluded complicated cases (e.g., renal abscess) and prostatitis. Our results should not be extrapolated to the whole population of bacteremic urinary tract infections. Lastly, both groups received a median of 5 days of intravenous therapy and 14 days of total treatment. This longer treatment duration may have reduced the chance to find a difference between the groups.
Future research is needed to further establish the safety, efficacy, and optimal duration of oral step down therapy for bacteremic urinary tract infections, in particular with oral beta-lactams. While observational studies can corroborate our findings, randomized controlled trials would provide clinicians the greatest confidence in using oral beta-lactam therapy as step down for bacteremic urinary tract infections.
In conclusion, oral beta-lactam step down in the setting of urinary tract infections with E. coli bacteremia had a similar clinical cure rate to that of oral fluoroquinolone step down. Given the potential adverse effects associated with fluoroquinolones, beta-lactams present a safe and efficacious alternative oral step-down agent.